Novo Nordisk launches Wegovy weight-loss drug in China

Novo Nordisk has launched its weight-loss drug Wegovy in China, targeting a market with over 180 million people living with obesity. This follows the drug's approval in June and aims to attract patients willing to pay out-of-pocket. The launch increases competition with Eli Lilly, which received approval for its weight-loss drug in July but has not yet launched it. Both companies are expanding production to meet the growing demand in a market expected to exceed $150 billion by 2030. Wegovy is priced at about $1,349 per month in the U.S., but Novo did not disclose its price in China. The drug will not be covered by China's national healthcare insurance.